• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Kite Pharma

edit

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient’s own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Recent Milestones

edit

• 
  Kite Pharma received $20M in Series A funding. (5/15/13)
  Posted 5/15/13 at 11:33pm via fiercebiotech.com
• 
  Kite Pharma received $15M in Series A funding. (3/9/11)
  Posted 3/9/11 at 7:49pm via yahoo.com

Videos

Screenshots

edit

Above: Kite Pharma
Uploaded: 3/10/11

Sources

1. Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors (finance.yahoo.com) [edit]
2. UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies (fiercebiotech.com) [edit]